Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.

PloS one - 1 Jan 2021

Mrozek Evelyn M, Bajaj Vineeta, Guo Yanan, Malinowska Izabela A, Zhang Jianming, Kwiatkowski David J

Abstract excerpt

Inactivating mutations in either TSC1 or TSC2 cause Tuberous Sclerosis Complex, an autosomal dominant disorder, characterized by multi-system tumor and hamartoma development. Mutation and loss of function of TSC1 and/or TSC2 also occur in a variety of sporadic cancers, and rapamycin and related drugs show highly variable treatment benefit in patients with such cancers. The TSC1 and TSC2 proteins function in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Screening Assays, Antitumor
Share to HSP90 Heat-Shock Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mechanistic Target of Rapamycin Complex 1

Share to Naphthyridines

Share to TOR Serine-Threonine Kinases

Share to Tuberous Sclerosis

Share to Tuberous Sclerosis Complex 1 Protein

Share to Tuberous Sclerosis Complex 2 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 33891611
DOI: 10.1371/journal.pone.0248380
PMCID: PMC8064564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.PMID 33891611Read ↗

Identification of Hsp90 inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancerSemantic proximity Read ↗

Therapeutic Approaches to Tuberous Sclerosis Complex: From Available Therapies to Promising Drug TargetsSemantic proximity Read ↗

Perfect match: mTOR inhibitors and tuberous sclerosis complexSemantic proximity Read ↗

Drug discovery targeting the mTOR pathwaySemantic proximity Read ↗

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disordersSemantic proximity Read ↗

The dual role of the TSC complex in cancer.Semantic proximity Read ↗

Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependentSemantic proximity Read ↗

Mammalian target of rapamycin: master regulator of cell growth in the nervous system.Semantic proximity Read ↗

Impact of genetic alterations on mTOR-targeted cancer therapy.Semantic proximity Read ↗

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis ComplexSemantic proximity Read ↗

A novel rapamycin analog is highly selective for mTORC1 in vivoSemantic proximity Read ↗

The tuberous sclerosis complex genes in tumor development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.